Teresa C. Guido, M.S.

Teresa C. Guido, M.S., is a distinguished research professional and scientific leader with more than three decades of experience in neuropathology, neuroscience, laboratory management, and biomedical research. Her career has focused extensively on Alzheimer’s disease research, particularly the study of amyloid pathology, immunotherapy, transgenic mouse models, and neurodegenerative disease mechanisms. Throughout her professional journey, she has combined scientific expertise with strong operational and laboratory leadership, contributing to research programs that have advanced understanding of Alzheimer’s disease and potential therapeutic approaches.

Guido spent much of her career at Elan Pharmaceuticals and Janssen Alzheimer Immunotherapy in South San Francisco, California, where she progressed through increasingly senior roles within the Neuropathology Department, ultimately serving as a Manager. In these positions, she managed research laboratories and imaging facilities, coordinated complex research operations, oversaw vendor and contract relationships, and collaborated with scientists, contract research organizations, academic laboratories, procurement teams, and other organizational partners. Her responsibilities included laboratory design and relocation, equipment management, tissue and reagent databases, research budgeting, procurement, contract administration, and the coordination of studies supporting Alzheimer’s and Parkinson’s disease research programs.

As a scientific researcher and laboratory leader, Guido has developed extensive expertise in immunochemistry, histology, microscopy, image analysis, tissue preparation, and the quantification of neuropathological changes in animal models. Her technical work has included studying amyloid plaques, neuritic burden, vascular amyloid, microhemorrhage, inflammatory cells, and other pathological features associated with neurodegenerative disease. She has also trained laboratory personnel in animal surgery, tissue preparation, immunohistochemical techniques, imaging protocols, statistical analysis, and laboratory safety. In addition, she has played a key role in maintaining research compliance, managing laboratory safety programs, coordinating inspections, and implementing operational systems that support reliable and efficient scientific research.

Guido’s contributions to neuroscience research are reflected in an extensive publication record. She has contributed to peer-reviewed studies published in prominent scientific journals, including Nature, Nature Medicine, The Journal of Neuroscience, The American Journal of Pathology, Proceedings of the National Academy of Sciences, European Journal of Neuroscience, Progress in Brain Research, and Neurobiology of Aging. Her research has addressed topics including the development of Alzheimer’s disease-like pathology in transgenic mice, the effects of amyloid-beta immunotherapy, antibody-mediated reduction of amyloid pathology, vascular amyloid, and the mechanisms underlying neurodegenerative disease. She has also contributed to numerous published scientific abstracts presented through the Society for Neuroscience.

A graduate of the University of California, Davis, Guido earned a Master of Science degree in Avian Sciences in 1991 and a Bachelor of Science degree in Avian Sciences in 1988. Her early research experience included work in avian developmental biology, primordial germ cell transfer, cell culture, microinjection, histology, artificial insemination, and poultry science. Throughout her career, she has been recognized with multiple professional honors, including the Janssen Encore Award and several Elan Awards of Excellence. Her combination of scientific knowledge, research leadership, technical expertise, and operational excellence has established her as a respected contributor to biomedical research and the continuing pursuit of a deeper understanding of neurodegenerative disease.

• Bachelor's degree from University of California, Davis
• Master's degree from University of California, Davis

• Encore Award
• Elan Award of Excellence — August 2004
• Elan Award of Excellence — November 2003
• Elan Award of Excellence — July 2003

Peer-Reviewed Publications

1. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G, Schenk D, Seubert P, and Games D. (2008). Immunotherapy reduces vascular amyloid-beta in PDAPP mice. Journal of Neuroscience, 28(27), 6787–6793.
2. Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, and Buttini M. (2004). Morphological characterization of Thioflavin-S-positive amyloid plaques in Alzheimer mice and effect of Aβ immunotherapy on their clearance. American Journal of Pathology, 165(3), 987–995.
3. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, and Yednock T. (2003). Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like pathology. PNAS, 100(4), 2023–2028.
4. Games D, Barbour R, Grajeda H, Guido T, Johnson-Wood K, Khan K, Soriano F, Seubert P, and Schenk D. (2000). Issues in establishing transgenic mouse models of neurodegenerative disease. European Journal of Neuroscience, 12 (Supplement 11), 441.
5. Games D, Bard F, Grajeda H, Guido T, Khan K, Soriano F, Vasquez N, Wehner N, Johnson-Wood K, Yednock T, Seubert P, and Schenk D. (2000). Prevention and reduction of AD-type pathology in PDAPP mice immunized with Aβ1-42. Annals of the New York Academy of Sciences, 920, 274–284.
6. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, and Yednock T. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine, 6(8), 916–919.
7. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yenock T, Games D, and Seubert P. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400(6740), 173–177.
8. Chen KS, Masliah E, Grajeda H, Guido T, Huang J, Khan K, Motter R, Soriano F, and Games D. (1998). Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice. Progress in Brain Research, 117, 327–334.
9. Games D, Guido T, Khan K, Soriano F, Justice A, Mallory M, Motter R, McConlogue L, Schenk D, and Masliah E. (1996). Development of age- and region-dependent progression of Alzheimer-type neuropathology in PDAPP transgenic mice. Neurobiology of Aging, 17 (Supplement 4), S156–S157.
10. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagoplan S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, et al. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature, 373(6514), 523–527.
11. Guido T, Abbott UK, and McCarrey JR. (1991). The interspecific transfer of avian primordial germ cells. Journal of Cellular Biochemistry, Supplement 15 (Part E), 204.

Published Abstracts

1. McConlogue LC, Zeller M, Khan K, Guido T, Games D, Chen K, Soriano F, Brigham B, Ni H, Grajeda H, Hu K, Johnson-Wood K, Motter R, Cook A, Tang P, Kholodenko D, Lee M, Suomensaari S, Sinha S, and Buttini M. (2003). Genetic ablation of BACE prevents neurodegenerative and plaque pathology. Society for Neuroscience Abstracts, 524.7.
2. Seubert P, Games D, Khan K, Buttini M, Bard F, Guido T, Grajeda H, Barbour R, Nguyen M, Kling K, Vasquez N, Schenk D, Hagen M, and Eldridge J. (2003). Comparative efficacy of different immunotherapeutic approaches in reducing AD-like neuropathology. Society for Neuroscience Abstracts, 133.3.
3. May PC, Altstiel L, Bender MH, Boggs LN, Calligaro DO, Fuson KS, Gitter BD, Hyslop PA, Jordan WH, Li WY, Mabry TE, Mark RJ, Ni B, Nissen JS, Porter WJ, Sorgen SG, Su Y, Audia JE, Dovey HF, Games D, John V, Freedman SB, Guido T, Johnson-Wood KL, Khan K, Latimer LH, Lieberburg IM, Seubert PA, Soriano F, Thorsett ED, and Schenk DB. (2001). Marked reduction of Aβ accumulation and beta-amyloid plaque pathology in mice upon chronic treatment with a functional gamma-secretase inhibitor. Society for Neuroscience Abstracts, 27(2), 1806.
4. Schenk D, Barbour R, Dunn W, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandervert C, Walker S, Wogulis M, Lieberburg I, Yednock T, Games D, and Seubert S. (1999). Attenuation of Alzheimer’s disease-like pathology in PDAPP mice by immunization with beta amyloid peptide. Society for Neuroscience Abstracts, 25(1–2), 1291.
5. Talpade D, Betaret R, Greenamyre JT, Pettus E, Guido T, and Games D. (1998). Profound mitochondrial dysfunction in transgenic mice overexpressing V717F beta-amyloid precursor protein. Society for Neuroscience Abstracts, 24(1–2), 729.
6. Games D, Chen K, Guido T, Hu K, Huang J, Khan K, Kholodenko D, Mallory M, McConlogue L, Motter R, Sisk A, Soriano F, Johnson-Wood K, Schenk D, and Masliah E. (1997). Progression of Alzheimer-type neuropathology in PDAPP mice. Society for Neuroscience Abstracts, 23(1–2), 1114.
7. Games D, Guido T, Khan K, Soriano F, Justice A, Mallory M, Motter R, McConlogue L, Schenk D, and Masliah E. (1996). Development of age- and region-dependent progression of Alzheimer-type neuropathology in PDAPP transgenic mice. Society for Neuroscience Abstracts, 22(1–3), 25.
8. Games D, Carr T, Guido T, Khan K, Soriano F, Tan H, McConlogue L, Lieberburg I, Schenk D, and Masliah E. (1995). Progression of Alzheimer-type neuropathology in PDAPP mice. Society for Neuroscience Abstracts, 21(1–3), 109.